GlassScriptPhysician profile
Cassandra Karney
NPI 1124776901
$4,030.86
in general payments reported to CMS, 2019-2025
33 companies · $1,285 in 2025
The $1,285 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $893 · 2024: $1,374 · 2025: $1,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530 · Education: $22.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,529.69 |
| Education | $22.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $419.87 | 2023-2025 | Veklury |
| Shionogi INC | $418.15 | 2022-2025 | Fetroja |
| Janssen Biotech, INC. | $344.66 | 2022-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $313.01 | 2022-2025 | Nuzyra |
| Tactile Systems Technology INC | $293.69 | 2022-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Merck Sharp & Dohme LLC | $293.19 | 2022-2025 | Dificid, Zerbaxa, Pifeltro |
| Inspire Medical Systems, INC. | $240.89 | 2024-2025 | Inspire |
| Mimedx Group, INC. | $224.19 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $173.32 | 2022-2025 | Xerava, Zevtera |
| Insmed, INC. | $130.90 | 2023-2025 | Arikayce, Brinsupri |
| Organogenesis INC. | $125.71 | 2024-2025 | Puraply Wound Matrix |
| Kerecis Limited | $124.17 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Mirati Therapeutics, INC. | $120.57 | 2023 | Krazati |
| Smith+Nephew, INC. | $111.03 | 2024-2025 | Collagenase Santyl, Pico, Grafix Pl |
| Abbvie INC. | $96.89 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $85.16 | 2024-2025 | Rukobia, Cabenuva, Dovato |
| Kci USA, INC. | $69.10 | 2023 | Activ.A.C. |
| Solventum Corporation | $68.90 | 2024-2025 | Snap, Activ.A.C. |
| Napo Pharmaceuticals INC | $48.40 | 2023-2024 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $44.61 | 2024 | Wainua |
| Melinta Therapeutics, LLC | $31.91 | 2024 | Rezzayo |
| Urgo Medical North America, LLC | $28.99 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Convatec INC. | $28.42 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $26.12 | 2022-2023 | Xarelto |
| Hartmann USA, INC. | $24.20 | 2025 | Zetuvit Plus 10x10 P10 |
| Aimmune Therapeutics, INC. | $21.75 | 2025 | Vowst |
| Pfizer INC. | $19.71 | 2023 | |
| Ferring Pharmaceuticals INC. | $19.18 | 2025 | Rebyota |
| Emd Serono, INC. | $19.11 | 2025 | |
| Tetraphase Pharmaceuticals, INC. | $18.04 | 2025 | |
| Itamar Medical INC | $17.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.77 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $13.47 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Karney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.